This compound is developed as an inhibitor of enzymes involved in inflammation, specifically the soluble epoxide hydrolase (sEH) enzyme, which metabolizes anti-inflammatory epoxides into inactive diols. Inhibiting sEH increases epoxide levels in the body, leading to reduced inflammation, pain relief, and potential prevention or slowing of tissue damage in various chronic diseases.

It has potential for treating inflammation-related conditions such as diabetes, kidney disease, liver disease, arthritis, and neurodegenerative disorders, with research demonstrating reduced neuronal damage and improved organ function in animal models.

Additionally, studies are evaluating its safety, efficacy, absorption, and distribution to prepare for future pharmaceutical development. As a key intermediate, its rigid cyclic structure and amide functionalities support its use in structure-activity relationship (SAR) studies for optimizing drug candidates.